PVH's Q2 results reflect EPS growth, driven by strong execution of the PVH+ Plan while revenues decline across all channels.
Vous n'êtes pas connecté
The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.
PVH's Q2 results reflect EPS growth, driven by strong execution of the PVH+ Plan while revenues decline across all channels.
BBY's second-quarter results reflect year-over-year bottom-line growth. Revenues, however, decline across Domestic and International segments.
SentinelOne's second-quarter fiscal 2025 results reflect improved revenues, driven by strong demand for its AI-powered security solutions.
HQY surpasses second-quarter expectations on robust HSA growth and improved margins. It also raises FY25 guidance.
HQY surpasses second-quarter expectations on robust HSA growth and improved margins. It also raises FY25 guidance.
GAP's second-quarter fiscal 2024 results gain due to strength in brands and other strategic efforts.
DOCU's second-quarter fiscal 2025 earnings and revenues are likely to increase year over year.
BRZE's second-quarter fiscal 2025 earnings and revenues are likely to increase year over year.
VEEV's fiscal second-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and...
The most important stock on the planet, NVIDIA (NVDA), just reported Q2 earnings after the closing bell today.